VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Vogelzang Discusses the Cabozantinib Trial Design

Nicholas J. Vogelzang, MD
Published: Wednesday, Jul 20, 2011

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the 9 arm trial design for cabozantinib (XL184) in multiple disease types. Explaining that after 12 weeks of treatment the enrolled patients received scans and blood tests. If they benefited after 12 weeks they were allowed to stay on the drug. If they were stable they could either continue or discontinue using the drug. If the cancer was shown to be growing at anytime throughout the trial or if there was undue toxicity the patients were made to discontinue the trial.
Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the 9 arm trial design for cabozantinib (XL184) in multiple disease types. Explaining that after 12 weeks of treatment the enrolled patients received scans and blood tests. If they benefited after 12 weeks they were allowed to stay on the drug. If they were stable they could either continue or discontinue using the drug. If the cancer was shown to be growing at anytime throughout the trial or if there was undue toxicity the patients were made to discontinue the trial.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x